The sensor automatically measures and continuously stores glucose readings day and night. The FreeStyle Libre flash glucose monitoring system is designed to liberate patients from the hassles of glucose monitoring- as quoted by Abbott. Let me explain a little about the FreeStyle Libre system. In a sense, I am pleading and begging the Government, along with the suppliers and providers, Abbott, to at least consider, even partially funding the cost of purchasing sensors for diabetics in the UK. 1 The frequency of self-monitoring blood glucose, which typically involves finger sticks and testing usinįund The Life Changing Libre Sensor Diabetic Blood Glucose Monitoring SystemĪs a type 1 diabetic, I am actively and desperately seeking funding and help towards the Freestyle Libre monitoring system/sensors. Image courtesy of Image courtesy of Abbott Diabetes Care People living with diabetes must regularly monitor their glucose (blood sugar) levels to confirm and treat low blood sugar, or hypoglycemia, to adjust their dosage of insulin, and to provide information to their health care providers about their diabetes management. A consumer version of the FreeStyle Libre Pro system intended for personal use by patients with diabetes is currently awaiting regulatory approval in the US. Canadian pricing is not available, but cost-effectiveness analyses conducted in the UK and other European countries have concluded that it is cost-effective compared with the self-monitoring of blood glucose. Although the FreeStyle Libre Pro system is approved for use in Canada, it is not yet commercially available here. The available evidence suggests that the performance and accuracy of the FreeStyle Libre Pro system is comparable to conventional methods of glucose monitoring, that it may reduce periods of hypoglycemia, or low blood sugar, and that it has high patient satisfaction. The FreeStyle Libre Pro is a glucose monitoring system intended to replace finger-stick tests it uses a sensor implanted in the arm that a health care provider scans with a specialized reader for a record of glucose levels, trends, and patterns in people with diabetes. 158Flash Glucose Monitoring System for Diabetes Eugenia Palylyk-Colwell and Caitlyn Ford. CADTH Issues in Emerging Health Technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health 2016. A service of the National Library of Medicine, National Institutes of Health. Abbott already markets the device in Europe and Canada, and a large chunk of growth in its international diabetes care sales is comingįlash Glucose Monitoring System For Diabetes - Cadth Issues In Emerging Health Technologies - Ncbi Bookshelf In the near term, we believe that the adoption of the recently launched blood glucose monitoring system Freestyle Libre Flash will be a key trigger to watch out for. While healthcare access is improving in these markets, price sensitivity will continue to offer ideal market conditions for generics, which is where Abbott focuses. This growth was driven by emerging markets including Brazil, Russia, India and China. In addition, the Pharmaceuticals business, which is relatively smaller than its other business segments, grew in double digits. We believe that Abbotts Diagnostics business could earn as much as $10 billion in annual revenue by 2024. Its Diagnostics segment grew more than 5%, and with the closure of the Alere acquisition and the launch of Alinity systems in Europe, we expect the momentum to continue going forward. Overall, we are more positive about Abbott than before. However, the company acknowledged some signs of stabilization, and the situation should become clearer early next year when new food safety regulations go into effect. Abbott has suffered some headwinds in China due to the weakness in the countrys pediatric nutrition market. However, the weakness in its Nutritionals business continued in China as well as some other international markets. On the plus side, the company posted impressive operational growth in the Pharmaceuticals, Diagnostics and Medical Devices businesses. Our price estimate is still slightly belowthe market price. Abbott Labs Price Estimate Revised On Operational GrowthĪbbott Labs Price Estimate Revised On Operational Growth We have revised our price estimate for Abbott Labs stock upwards to $49 in light of its recently announced third quarter results.
0 Comments
Leave a Reply. |